Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN668: Rate 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN668: Injection Rate 1 | DRUG | Subjects will receive REGN668 via SC injection |
| REGN668: Injection Rate 2 | DRUG | Subjects will receive study drug via alternate delivery (if necessary) |
Inclusion Criteria: 1. Male or female subjects 18 to 55 years of age. 2. Body weight between 60 kg and 80 kg, body mass index between 20 and 30 kg/m2 inclusive. 3. NHV as evidenced by comprehensive clinical assessment (detailed medical history and complete physical examination). 4. Normal resting b...
REGN668 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial assessing its safety, tolerability, pharmacokinetics, and immunogenicity when administered subcutaneously. It is not approved for any indication.
REGN668 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. The company conducted a Phase 1 study of REGN668 in healthy volunteers in the United States.
REGN668 is in Phase 1 clinical development. The only trial listed for REGN668 is a completed Phase 1 study. It is an investigational drug and has not been approved by regulatory authorities.
REGN668 has one completed clinical trial, NCT01484600, titled "Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers." This Phase 1 study enrolled 36 healthy participants in the United States.
The Phase 1 trial of REGN668, NCT01484600, was randomized and controlled, but it was not double-blind. The study enrolled healthy volunteers aged 18 years and older, with a total enrollment of 36 participants.